-+ 0.00%
-+ 0.00%
-+ 0.00%

aTyr Pharma's ATYR2810 Reduces Osteosarcoma Tumor Growth in Preclinical Studies

PUBT·11/19/2026 12:06:12
Listen to the news
aTyr Pharma's ATYR2810 Reduces Osteosarcoma Tumor Growth in Preclinical Studies
  • aTyr Pharma announced preclinical ATYR2810 results scheduled for presentation November 19, 2026, at the Connective Tissue Oncology Society meeting in Seoul.
  • The NRP2-targeting antibody reduced osteosarcoma tumor growth and lung metastases in mouse studies without evidence of overt toxicity.
  • Anti-tumor effects persisted following treatment withdrawal, supporting potential clinical development in aggressive cancers.
  • ATYR2810 remains in preclinical development, with nonhuman primate toxicology testing and manufacturing completed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190700PRIMZONEFULLFEED9880766) on November 19, 2026, and is solely responsible for the information contained therein.